Emerging Company Profile
Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria
Microbiome company emerges with $50M, lead program to treat hyperoxaluria with designed consortia
Microbiome company with Venrock, Stanford founders emerges with $50 million series A round and a lead program to treat hyperoxaluria with a designed microbiome able to persist in patients’ guts.
Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut.